Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study
Authors:
- 25 August 2010
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 55 (4) , 629-638
Abstract
Background: Demethylating agents may alter the expression of genes involved in chemotherapy resistance. We conducted a phase I trial to determine the toxicity and molecular effects of the demethylating agent, decitabine, followed by doxorubicin and cyclophosphamide in children with refractory solid tumors.Procedure: Stratum A included children with any solid tumor; Stratum B included neuroblastoma patients only. Patients received a 1‐hr decitabine infusion for 7 days, followed by doxorubicin (45 mg/m2) and cyclophosphamide (1 g/m2) on day 7. Pharmacokinetic studies were performed after the first dose of decitabine. Biological studies included methylation and gene expression analyses of caspase‐8, MAGE‐1 and fetal hemoglobin (HbF), and expression profiling of pre‐ and post‐treatment peripheral blood and bone marrow cells.Results: The maximum‐tolerated dose of decitabine was 5 mg/m2/day for 7 days. Dose‐limiting toxicities at 10 mg/m2/day were neutropenia and thrombocytopenia. Decitabine exhibited rapid clearance from plasma. Three of 9 patients in Stratum A and 4/12 patients in Stratum B had stable disease for ≥4 months. Sustained MAGE‐1 demethylation and increased HbF expression were observed in the majority of patients post‐treatment (12/20 and 14/16, respectively). Caspase‐8 promoter demethylation and gene expression were seen in 2/7 bone marrow samples. Differentially expressed genes were identified by microarray analysis.Conclusion: Low‐dose decitabine when combined with doxorubicin/cyclophosphamide has tolerable toxicity in children. However, doses of decitabine capable of producing clinically relevant biologic effects were not well tolerated with this combination. Alternative strategies of combining demethylating agents with non‐cytotoxic, biologically targeted agents such as histone deactelyase inhibitors should be explored. Pediatr Blood Cancer. 2010;55:629–638.Keywords
This publication has 51 references indexed in Scilit:
- Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancerBMC Cancer, 2008
- Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemiaCancer, 2007
- Doxorubicin Inhibits DNMT1, Resulting in Conditional ApoptosisMolecular Pharmacology, 2004
- Methylation-Associated Silencing of the Heat Shock Protein 47 Gene in Human NeuroblastomaCancer Research, 2004
- Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignanciesBlood, 2004
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences, 2003
- Hypermethylation‐mediated regulation of CD44 gene expression in human neuroblastomaGenes, Chromosomes and Cancer, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumoursOncogene, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000